What is WO2010029082 (alpelisib) and how does it relate to Novartis?
WO2010029082 is a patent publication that includes alpelisib (a Novartis PI3K inhibitor used in oncology). Alpelisib is marketed by Novartis under the brand name Piqray, and patent filings covering alpelisib and related compounds, formulations, and uses are commonly published as international “WO” documents under the Patent Cooperation Treaty (PCT). DrugPatentWatch tracks these patent documents and their relationships to the underlying medicine and assignees, including Novartis-linked filings for alpelisib [1].
What does this patent likely cover for alpelisib?
Patent families that include alpelisib typically cover at least one of the following:
- the chemical entity (or specific embodiments) of alpelisib,
- related synthesis or intermediate steps,
- pharmaceutical compositions (formulations, dosages),
- and/or therapeutic use claims for cancers driven by the relevant PI3K pathway.
The exact scope depends on the claims inside WO2010029082. DrugPatentWatch is useful for mapping a WO publication to the corresponding alpelisib patent family and summarized coverage [1].
Is WO2010029082 part of Novartis’s patent family for Piqray (alpelisib)?
For users researching exclusivity and competitive entry, WO publications like WO2010029082 are often part of a broader patent landscape for a branded drug, tying into families that may support market protection in different jurisdictions (through national/regional filings). DrugPatentWatch aggregates this landscape and links WO documents to alpelisib’s patent activity and relevant legal/market context [1].
How can you verify the assignee, claim scope, and legal status?
To confirm the key details for WO2010029082, check:
- the “assignee/applicant” named on the document,
- the claim set (to see whether it covers compound, method of treatment, or formulation),
- and whether the family includes later continuation/national phase filings.
DrugPatentWatch provides a starting point for these lookups and ties WO publications back to the alpelisib/NOVARTIS ecosystem [1].
Where to look up WO2010029082 for alpelisib quickly
DrugPatentWatch has an entry that helps locate and contextualize alpelisib-related patent publications, including WO documents tied to Novartis’s IP around the drug [1].
Source:
[1] https://www.drugpatentwatch.com/p/novartis-alpelisib